Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids

Randomized Controlled Trial of Uterine Artery Embolization (UAE) Versus High-Intensity-Focused-Ultrasound (HIFU) for Treatment of Patients With Uterine Fibroids

This study aimed to evaluate the clinical effectiveness and adverse effects of Uterine Artery Embolization (UAE), High-Intensity-Focused-Ultrasound (HIFU) in treating patients with uterine fibroid.

Study Overview

• Status: Terminated
• Conditions: Uterine Fibroids
• Intervention / Treatment: Procedure: UAE; Procedure: HIFU

Detailed Description

The usual management for symptomatic uterine fibroid is surgery (myomectomy or hysterectomy), in the current study, uterine artery embolization (UAE) is a form of non-surgical and minimally invasive treatment, High-Intensity-Focused-Ultrasound (HIFU) is a form of non-invasive treatment that can be completed as an out-patient within hours. Embolization causes ischaemia and shrinkage of the fibroid and therefore symptomatic relieve. HIFU is a medical technology that has been used for cancer treatment. Energy is delivered from outside the body in a non-invasive manner to produce heat energy that causes necrosis and shrinkage of the uterine fibroid thereby relieves the symptoms due to the fibroid. It does not involve radiation. The clinical effectiveness of HIFU for uterine fibroid is unknown, however, based on the knowledge of the clinical effectiveness of HIFU on liver cancer and pancreatic cancer, there is reasonable ground to believe that HIFU is effective for uterine fibroid.

• Study Type: Interventional
• Enrollment (Actual): 85
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Hong Kong
  • Hong Kong, Hong Kong
    • Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong
  • Hong Kong, Hong Kong
    • Department of Obstectrics and Gynaecology, Prince of Wales Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 47 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female gender
• Age between 30 and 47
• Pre or peri menopausal with Follicle-stimulating hormone (FSH) less than 40 mIU/ml
• Weight less than 140kg (or 310lbs) and Body Mass Index (BMI) less than 33
• Cervical cytology no more severe than low grade SIL
• Negative urine pregnancy test
• Uterine size less than 24 weeks based on physical exam assessment
• History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain. Excessive uterine bleeding will be evidenced by either one of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss OR pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection
• Dominant intramural fibroid greater than or equal to 3 cm and less than or equal to 12 cm on imaging.
• Good health other than history of leiomyomas. Chronic medications may be acceptable at the discretion of the research team.
• No future fertility wish.
• Are using abstinence, mechanical (condoms, diaphragms) or sterilization methods of contraception and are willing to continue using them throughout the study.
• Willing and able to give informed consent.
• Willing and able to comply with study requirements.
• Normal menstrual cycle with endometrial pathology excluded
• Normal renal function
• Normal liver function
• Platelet count greater than 50 K/microL
• Normal coagulation profile

Exclusion Criteria:

• Significant abnormalities in the history, physical or laboratory examination
• History of or current thromboembolic event (deep vein thrombosis, pulmonary embolus, stroke)
• Other pelvic mass indicated by history or MR imaging such as endometriosis, ovarian tumor, acute or chronic pelvic inflammatory disease
• Desire for future pregnancy
• Pregnant or Positive pregnancy test
• Lactation
• Unexplained vaginal bleeding
• Untreated severe cervical dysplasia
• Intrauterine device
• Need for interval use of narcotics
• Extensive scarring along anterior lower abdominal wall (greater than 50% of area) or scar tissue or surgical clips in the direct path of the HIFU
• Pedunculated submucosal or subserosal fibroid of size ≧5cm and with a stalk less than 25% of the maximal fibroid diameter.
• Genetic causes of leiomyomata
• Known recent rapid growth of fibroids, defined as a doubling in size in 6 months
• Patient unwilling to receive non-surgical treatment
• Contraindication to MRI due to severe claustrophobia or implanted metallic device.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: UAE treatment; After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment	Procedure: UAE; The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
Active Comparator: HIFU; After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment	Procedure: HIFU; Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment success rate	Technical success of treatment procedure and absence of symptoms of fibroid	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of procedure related complication	Complications after treatment procedures will be recorded during each hospital admission and during each HIFU treatment session. Major adverse events will be reported. Complications that occur prior to a clinical visit will be documented and graded in each clinical visit at 1, 3, 6 and 12 month after treatment.	1, 3, 6, 12 months after treatment
volume change of the fibroids	Assessed by 3 Dimensional ultrasonography (USG)	6, 12 months after treatment
Degree of infarction of the fibroids	Contrast enhanced magnetic resonance imaging (MRI) is used to assess the degree of infarction, which is defined as non-perfused tissue on contrast MRI.	3, 15 months after treatment
Vascularity of the fibroids	Assessed by contrast enhanced USG. Vascularity of the fibroid will be classified into six categories: 0%, <25%, 25 to 50%, >50 to 75%, >75%, 100%.	6, 12 months after treatment

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong
• Collaborators: Prince of Wales Hospital, Shatin, Hong Kong
• Investigators: Principal Investigator: Simon CH Yu, MD, FRCR, Chinese University of Hong Kong

Study record dates

Study Major Dates

• Study Start: May 1, 2009
• Primary Completion (Actual): December 1, 2015
• Study Completion (Actual): December 1, 2015

Study Registration Dates

• First Submitted: April 4, 2013
• First Submitted That Met QC Criteria: April 16, 2013
• First Posted (Estimate): April 18, 2013

Study Record Updates

• Last Update Posted (Actual): August 30, 2019
• Last Update Submitted That Met QC Criteria: August 28, 2019
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Connective Tissue Diseases; Neoplasms, Connective Tissue; Neoplasms, Muscle Tissue; Leiomyoma; Myofibroma
• Other Study ID Numbers: VIR-13-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No